NCT06923956View on ClinicalTrials.gov

Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions.

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

December 18, 2024

Study Completion Date

February 8, 2025

Conditions
HypercholesterolaemiaMixed DyslipidaemiaCardiovascular Diseases
Interventions
DRUG

Bempedoic Acid Film Coated Tablet

1 tablet of 180 mg Bempedoic Acid

DRUG

Nilemdo® (Bempedoic Acid) Film-coated tablets

1 tablet of 180 mg Bempedoic Acid

Trial Locations (1)

201301

Cliantha Research Limited, Noida

All Listed Sponsors
lead

Humanis Saglık Anonim Sirketi

INDUSTRY

NCT06923956 - Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions. | Biotech Hunter | Biotech Hunter